Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.46 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.45 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23229979 | 0.89 | TGFBR1 (0.57) | TGFBR1MAPK14PRKD1KDRPDGFRA | |
| SCHEMBL22910410 | 0.87 | TGFBR1 (0.54) | TGFBR1MAPK14PRKD1KDRPDGFRA | |
| SCHEMBL22910493 | 0.87 | TGFBR1 (0.47) | TGFBR1MAPK14PRKD1KDRPDGFRA | |
| SCHEMBL22910689 | 0.85 | TGFBR1 (0.56) | TGFBR1MAPK14PRKD1KDRPDGFRA | |
| SCHEMBL22910678 | 0.85 | TGFBR1 (0.53) | TGFBR1MAPK14PRKD1KDRPDGFRA | |
| SCHEMBL22910498 | 0.84 | TGFBR1 (0.55) | TGFBR1MAPK14PRKD1KDRRIPK2 | |
| SCHEMBL23230027 | 0.83 | TGFBR1 (0.62) | TGFBR1MAPK14PRKD1KDRPDGFRA | |
| SCHEMBL23330288 | 0.83 | TGFBR1 (0.62) | TGFBR1MAPK14PRKD1KDRPDGFRA | |
| SCHEMBL22910511 | 0.82 | TGFBR1 (0.52) | TGFBR1MAPK14PRKD1 | |
| SCHEMBL22910512 | 0.82 | TGFBR1 (0.55) | TGFBR1MAPK14PRKD1KDRPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-06 | — | — | US | disclosed |
| WO-2021072203-A1 | TGFBETAR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021011834-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | ALK, ALKBH5, ACVR1 | TGFBR1 36/4885MAPK14 2693/4885PRKD1 3165/4885 |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | TGFBR2, ASGR1, TGFBR1 | TGFBR1 3/4885MAPK14 2334/4885PRKD1 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.